Nevada 2023 Regular Session

Nevada Senate Bill SB201

Introduced
3/2/23  
Refer
3/2/23  
Report Pass
4/24/23  
Refer
4/24/23  

Caption

Revises provisions governing pharmacists. (BDR 54-582)

Impact

The implications of SB 201 on state laws are significant, particularly in terms of pharmacy practice and healthcare regulations. By allowing pharmacists to play a more integral part in patient care and medical service provision, the bill aligns pharmacy practice with modern healthcare delivery needs. This initiative could lead to increased access to care, particularly for patients in underserved areas, while also potentially relieving pressure on other healthcare professionals by enabling pharmacists to manage more health-related tasks.

Summary

Senate Bill 201 revises provisions governing pharmacists in Nevada by empowering them to collect laboratory specimens using various methods beyond just fingersticks or swabs. The bill seeks to expand the capabilities of pharmacists to order and perform essential laboratory tests necessary for therapy, thereby broadening their role in patient care. Furthermore, it ensures that public and private health plans, including Medicaid, provide coverage for services rendered by pharmacists at a reimbursement rate comparable to those for physicians and other healthcare providers. The intent is to enhance healthcare access and promote stronger collaboration between pharmacists and the healthcare system.

Sentiment

Sentiment around SB 201 appears largely supportive among healthcare providers and pharmacy advocates who view the bill as a proactive measure to adapt to the evolving landscape of healthcare delivery. The bill is seen as an opportunity to enhance public health outcomes through greater pharmacist engagement. Opponents may express concerns regarding the potential for pharmacists to exceed their training or create overlaps in responsibilities traditionally held by other healthcare professionals, indicating a need for careful implementation and oversight.

Contention

Notable points of contention might stem from debates over the qualifications required for pharmacists to conduct laboratory tests and the implications for patient safety. Additionally, discussions may arise over the financial effects on insurance providers who would be required to adjust their coverage protocols and reimbursement strategies to include pharmacist-provided services. Ensuring proper training and adherence to safety protocols for pharmacists engaging in testing will be critical to the successful enactment of the bill.

Companion Bills

No companion bills found.

Similar Bills

NV AB186

Revises provisions governing pharmacists. (BDR 54-344)

NV SB354

Revises provisions relating to health insurance coverage of prescription drugs. (BDR 57-1041)

NV SB439

Revises provisions relating to communicable diseases. (BDR 40-987)

NV AB156

Revises provisions relating to substance use disorders. (BDR 40-331)

NV SB118

Revises requirements relating to coverage under Medicaid for certain services provided by pharmacists. (BDR 38-218)

MN HF2466

Pharmacists authorized to prescribe, dispense, and administer drugs to prevent acquisition of human immunodeficiency virus; pharmacists authorized to order, conduct, and interpret laboratory tests necessary for therapy that uses drugs to prevent acquisition of human immunodeficiency virus.

MN SF2320

Pharmacists authorization to prescribe, dispense and administer drugs to prevent the acquisition of human immunodeficiency virus

NV AB74

Revises provisions relating to insurance. (BDR 57-256)